Collegium Pharmaceutical, Inc.
As of Oct 22, 2026, Collegium Pharmaceutical is in Stage 4, the downtrend phase, now in week 11 (since Aug 11, 2026). It closed at $23.50, 52.8% below its 52-week high and below its 200-day average, which is falling.
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is COLL early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
COLL among Drug Manufacturers - Specialty & Generic48th of 84 by relative strength
All 84 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | CPIX | Stage 2 · wk 23 | 98 | +6.8% |
| 2 | ETON | Stage 2 · wk 30 | 97 | −10.1% |
| 3 | ANIK | Stage 2 · wk 15 | 96 | +3.5% |
| 4 | IRWD | Stage 3 · wk 3 | 96 | −16.4% |
| 5 | TEVA | Stage 2 · wk 9 | 95 | +3.1% |
| 6 | AMRX | Stage 2 · wk 19 | 95 | +5.9% |
| 7 | KNSA | Stage 2 · wk 73 | 95 | +6.2% |
| 8 | AMLX | Stage 2 · wk 15 | 93 | −6.6% |
| …48 | COLL | Stage 4 · wk 11 | 31 | +4.7% |
Collegium Pharmaceutical: quick answers
What stage is Collegium Pharmaceutical in?
As of Oct 22, 2026, Collegium Pharmaceutical (COLL) is in Stage 4, the downtrend phase. It entered Stage 4 on Aug 11, 2026 and is in week 11. What the four stages mean
Is Collegium Pharmaceutical in an uptrend?
No. Collegium Pharmaceutical is in a Stage 4 downtrend. It trades 30.8% below its 200-day average, which is falling.
How far is Collegium Pharmaceutical from its 52-week high?
Collegium Pharmaceutical closed at $23.50 on Oct 22, 2026, 52.8% below its 52-week high of $49.84. Its 52-week low is $21.53.
How has Collegium Pharmaceutical performed over the past year?
As of Oct 22, 2026, Collegium Pharmaceutical is down 33.5% over the past year and down 48.4% so far in 2026.
Which sector and industry is Collegium Pharmaceutical in?
Collegium Pharmaceutical is in the Drug Manufacturers - Specialty & Generic industry, part of the Health Care sector.
About this companyHealth Care· Drug Manufacturers - Specialty & Generic
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. Collegium Pharmaceutical, Inc. was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. The company was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.